About Us

Tikva Allocell is focused on creating therapy using our proprietary IP protected platform to drive the next breakthrough in cancer therapy.
At Tikva Allocell we inspire hope today, for a better tomorrow.

Our Mission

Allogeneic EBVST Platform

Effective and affordable therapy

Headquartered in the bustling city-state of Singapore, Tikva Allocell is established by a seasoned cell therapy development team with practical knowledge and experience, to develop effective, available and affordable “off-the-shelf” T cell therapies by leveraging excellent safety profile of Allogeneic Epstein-Barr Virus (EBV)-Specific T cells (ALLO EBVST) and proprietary IP protected technologies that enhance the T cell performance to treat cancer.

Our History

Sorry, we couldn't find any posts. Please try a different search.

Founding Team

Founded by Key Opinion Leaders in the field.

Dr Ivan Horak

Founder & CEO

Prof Malcolm Brenner

Co-Founder

Prof Cliona Rooney

Co-Founder

Prof Helen Heslop

Co-Founder

Craig Ari Loren, MBA

Co-Founder & COO
Scientific Advisory Board

Advised by experienced clinicians in oncology.

Scientific Advisory Board Chairperson

Dr Stephen Gottschalk​

Chair, Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Research Hospital
Read more...
Scientific Advisory Board Members

Dr Chng Wee Joo

Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

Dr Cliona Rooney

Professor, Center for Cell and Gene Therapy, Baylor College of Medicine

Dr Dmitriy Zamarin

Medical Oncologist, Gynecology, Memorial Sloan Kettering Cancer Center

Dr Helen Heslop

Director, Center for Cell and Gene Therapy, Baylor College of Medicine

Dr Josep Tabernero

Head, Medical Oncology Department, Vall d’Hebron University Hospital in Barcelona, and Director, Vall d’Hebron Institute of Oncology

Dr Malcolm Brenner

Founding Director of Center for Cell & Gene Therapy, Baylor College of Medicine

Dr Pam Ohashi

Professor, Department of Immunology, University of Toronto, Co-Director, the Campbell Family Institute for Breast Cancer Research

Dr Rafi Ahmed

Professor, Department of Microbiology and Immunology, Emory University School of Medicine, and Director, Emory Vaccine Center

Dr Quasim Waseem

Professor of Cell & Gene Therapy, University College London Institute of Child Health
Managing Team

Managed by seasoned experts in biotech.

Wilson Cheung

Chief Financial Officer

Dr Paul Nadler

Chief Medical Officer

Dr Debra Wood

VP, Clinical Operations

TBA

VP, Regulatory Affairs
Capabilities

Taking Innovation Forward to the Clinic

Advancing Cell Therapies

Scientific Innovation

Engineering next generation CARs and CAR T therapies
Pharmacology and preclinical efficacy studies in disease-relevant models
From Discovery to Production Ready

Process Development & Analytical Science

Translation from research to production of CAR-T cell therapies
Design, development and validation of assays for specification and characterization of CAR-T products
Regulatory Filing & Clinical Trials

Clinical & Regulatory Expertise

Track record of meeting CMC, pharmacology, toxicology and clinical requirements for CAR-T products
Rich experience in running early to late phase cell therapy oncology clinical trials